External validation of NTCP-models for radiation pneumonitis in lung cancer patients treated with chemoradiotherapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
09 2023
Historique:
received: 20 04 2022
revised: 16 05 2023
accepted: 02 06 2023
medline: 21 8 2023
pubmed: 17 6 2023
entrez: 16 6 2023
Statut: ppublish

Résumé

Normal tissue complication probability (NTCP) models can be used to estimate the risk of radiation pneumonitis (RP). The aim of this study was to externally validate the most frequently used prediction models for RP, i.e., the QUANTEC and APPELT models, in a large cohort of lung cancer patients treated with IMRT or VMAT. [1-2] METHODS AND MATERIALS: This prospective cohort study, included lung cancer patients treated between 2013 and 2018. A closed testing procedure was performed to test the need for model updating. To improve model performance, modification or removal of variables was considered. Performance measures included tests for goodness of fit, discrimination, and calibration. In this cohort of 612 patients, the incidence of RP ≥ grade 2 was 14.5%. For the QUANTEC-model, recalibration was recommended which resulted in a revised intercept and adjusted regression coefficient (from 0.126 to 0.224) of the mean lung dose (MLD),. The APPELT-model needed revision including model updating with modification and elimination of variables. After revision, the New RP-model included the following predictors (and regression coefficients): MLD (B = 0.250), age (B = 0.049, and smoking status (B = 0.902). The discrimination of the updated APPELT-model was higher compared to the recalibrated QUANTEC-model (AUC: 0.79 vs. 0.73). This study demonstrated that both the QUANTEC- and APPELT-model needed revision. Next to changes of the intercept and regression coefficients, the APPELT model improved further by model updating and performed better than the recalibrated QUANTEC model. This New RP-model is widely applicable containing non-tumour site specific variables, which can easily be collected.

Identifiants

pubmed: 37327975
pii: S0167-8140(23)00273-6
doi: 10.1016/j.radonc.2023.109735
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109735

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anne G H Niezink (AGH)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: a.g.h.niezink@umcg.nl.

Arjen van der Schaaf (A)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Robin Wijsman (R)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Olga Chouvalova (O)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Anthonie J van der Wekken (AJ)

Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Steven R Rutgers (SR)

Department of Pulmonology, Treant Hospital Group, Scheper Hospital, Emmen, the Netherlands.

Remge M Pieterman (RM)

Department of Pulmonary Diseases, Ommelander Hospital Groningen, Scheemda, the Netherlands.

John W G van Putten (JWG)

Department of Pulmonary Diseases, Martini Hospital Groningen, Groningen, the Netherlands.

Sander M de Hosson (SM)

Department of Pulmonary Diseases, Wilhelmina Hospital Assen, Assen, the Netherlands.

Annija H D van der Leest (AHD)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Jan F Ubbels (JF)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Marleen Woltman-van Iersel (M)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Joachim Widder (J)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria.

Johannes A Langendijk (JA)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Christina T Muijs (CT)

Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH